Sign in
COYA Stock Price, Chart, Stats & News
Coya Therapeutics, Inc.
Save
98.15M
Market cap
–
Current P/E
–
Forward P/E
COYA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.66% |
Operating margin | -255.05% |
Pretax margin | -267.10% |
Net margin | -267.14% |
Effective tax rate | -0.01% |
ROA | -42.49% |
ROE | -64.33% |
D/E | – |
Interest coverage ratio | – |
COYA valuation
P/E | – |
P/S | 8.34x |
P/B | 1.54x |
P/CF | -0.01x |
P/FCF | -0.01x |
P/OCF | -0.01x |
PEG | 0.22x |
EV multiple | -5.59x |
About
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS).
Similar securities
Based on sector and market capitalization
Report issue